首页> 外文期刊>Journal of Breast Cancer >Preoperative Magnetic Resonance Imaging and Survival Outcomes in T1–2 Breast Cancer Patients Who Receive Breast-Conserving Therapy
【24h】

Preoperative Magnetic Resonance Imaging and Survival Outcomes in T1–2 Breast Cancer Patients Who Receive Breast-Conserving Therapy

机译:接受保乳疗法的T1-2乳腺癌患者的术前磁共振成像和生存结果

获取原文
           

摘要

Purpose The purpose of the study was to evaluate the effect of preoperative magnetic resonance imaging (MRI) on survival outcomes for breast cancer. Methods A total of 954 patients who had T1–2 breast cancer and received breast-conserving therapy (BCT) between 2007 and 2010 were enrolled. We divided the patients according to whether they received preoperative MRI or not. Survival outcomes, including locoregional recurrence-free survival (LRRFS), recurrence-free survival (RFS), and overall survival (OS), were analyzed. Results Preoperative MRI was performed in 743 of 954 patients. Clinicopathological features were not significantly different between patients with and without preoperative MRI. In the univariate analyses, larger tumors were marginally associated with poor LRRFS compared to smaller tumors (hazard ratio [HR], 3.22; p =0.053). Tumor size, histologic grade, estrogen receptor (ER), progesterone receptor (PR), hormonal therapy, and adjuvant chemotherapy status were associated with RFS. Larger tumor size, higher histologic grade, lack of ER and PR expression, and no hormonal therapy were associated with decreased OS. Tumor size was associated with LRRFS in the multivariate analyses (HR, 4.19; p =0.048). However, preoperative MRI was not significantly associated with LRRFS, RFS, or OS in either univariate or multivariate analyses. Conclusion Preoperative MRI did not influence survival outcomes in T1–2 breast cancer patients who underwent BCT. Routine use of preoperative MRI in T1–2 breast cancer may not translate into longer RFS and OS.
机译:目的本研究的目的是评估术前磁共振成像(MRI)对乳腺癌生存结果的影响。方法纳入2007年至2010年间共954例患有T1–2乳腺癌并接受保乳治疗(BCT)的患者。我们根据患者是否接受术前MRI进行划分。分析了生存结果,包括局部无复发生存期(LRRFS),无复发生存期(RFS)和总体生存期(OS)。结果954例患者中有743例进行了术前MRI检查。有无术前MRI的患者之间的临床病理特征无明显差异。在单变量分析中,与较小的肿瘤相比,较大的肿瘤与较差的LRRFS略相关(危险比[HR],3.22; p = 0.053)。肿瘤大小,组织学分级,雌激素受体(ER),孕激素受体(PR),激素治疗和辅助化疗状态均与RFS相关。更大的肿瘤大小,更高的组织学等级,缺乏ER和PR表达以及没有激素治疗与OS降低有关。在多变量分析中,肿瘤大小与LRRFS相关(HR,4.19; p = 0.048)。但是,在单变量或多变量分析中,术前MRI与LRRFS,RFS或OS均无显着相关性。结论术前MRI不影响接受BCT的T1-2乳腺癌患者的生存结果。在T1-2乳腺癌中常规使用术前MRI可能不会转化为更长的RFS和OS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号